---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-070944"
form_type: "8-K"
ticker: "PEPG"
cik: "0001835597"
company_name: "PepGen Inc."
filed_at: "2023-12-18T23:59:59+00:00"
generated_at: "2026-06-07T11:26:20.832195+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# PepGen doses first patient in Phase 1 FREEDOM-DM1 trial; data expected in 2024

## Summary
- First patient dosed in Phase 1 FREEDOM-DM1 trial of PGN-EDODM1 for myotonic dystrophy type 1.
- Safety, transcript splicing correction, and clinical outcome data at 5 mg/kg dose expected in 2024.
- UK MHRA clearance obtained, enabling enrollment in third country (US, Canada, UK).
- Trial to enroll ~24 adults; single ascending doses from 5 to 20 mg/kg with safety-based escalation.
- CEO James McArthur calls dosing a significant milestone toward transformative therapy for DM1.

## SEC filing metadata
- accession: 0000950170-23-070944
- form_type: 8-K
- ticker: PEPG
- cik: 0001835597
- company_name: PepGen Inc.
- filed_at: 2023-12-18T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835597/000095017023070944/0000950170-23-070944-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835597/000095017023070944/pepg-20231218.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-070944
- JSON: https://secwatch.observer/filing/0000950170-23-070944.json
- Plain text: https://secwatch.observer/filing/0000950170-23-070944.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.